EGFR and neoplasm: Through genetic testing, we identified a high prevalence of driver gene mutations in all CMPTs by whole exon sequencing, and we also found a non-frame shift insertion mutation in exon 20 of EGFR in the tumor tissues, which has been considered to be a key driving gene for lung cancer (Supplementary Figure S5).